JP2022527405A5 - - Google Patents
Info
- Publication number
- JP2022527405A5 JP2022527405A5 JP2021560206A JP2021560206A JP2022527405A5 JP 2022527405 A5 JP2022527405 A5 JP 2022527405A5 JP 2021560206 A JP2021560206 A JP 2021560206A JP 2021560206 A JP2021560206 A JP 2021560206A JP 2022527405 A5 JP2022527405 A5 JP 2022527405A5
- Authority
- JP
- Japan
- Prior art keywords
- length
- tgcd3
- partial
- cells
- full
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962832622P | 2019-04-11 | 2019-04-11 | |
| US62/832,622 | 2019-04-11 | ||
| PCT/US2020/027327 WO2020210398A1 (en) | 2019-04-11 | 2020-04-08 | CD3 RECONSTITUTION IN ENGINEERED iPSC AND IMMUNE EFFECTOR CELLS |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2022527405A JP2022527405A (ja) | 2022-06-01 |
| JP2022527405A5 true JP2022527405A5 (cg-RX-API-DMAC10.html) | 2023-04-18 |
| JP7783746B2 JP7783746B2 (ja) | 2025-12-10 |
Family
ID=72750569
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021560206A Active JP7783746B2 (ja) | 2019-04-11 | 2020-04-08 | 操作されたiPSCおよび免疫エフェクター細胞におけるCD3の再構成 |
Country Status (12)
Families Citing this family (22)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US11629340B2 (en) | 2017-03-03 | 2023-04-18 | Obsidian Therapeutics, Inc. | DHFR tunable protein regulation |
| EP4578507A3 (en) | 2018-11-01 | 2025-11-12 | Gracell Biotechnologies (Shanghai) Co., Ltd. | Compositions and methods for t cell engineering |
| KR20230040337A (ko) | 2020-06-19 | 2023-03-22 | 페이트 세러퓨틱스, 인코포레이티드 | 면역요법 사용을 위한 iPSC-유래 이펙터 세포 유형들의 조합 |
| CN114525259B (zh) * | 2020-11-03 | 2025-02-14 | 南京北恒生物科技有限公司 | 靶向cd7的嵌合抗原受体及其用途 |
| WO2022098914A1 (en) * | 2020-11-04 | 2022-05-12 | Fate Therapeutics, Inc. | Engineered ipsc and persistent immune effector cells |
| WO2022099297A1 (en) * | 2020-11-04 | 2022-05-12 | Fate Therapeutics, Inc. | Multiplexed engineered ipsc and immune effector cells targeting solid tumors |
| US11459372B2 (en) | 2020-11-30 | 2022-10-04 | Crispr Therapeutics Ag | Gene-edited natural killer cells |
| IL303269A (en) | 2020-12-03 | 2023-07-01 | Century Therapeutics Inc | Genetically engineered cells and uses thereof |
| US11661459B2 (en) | 2020-12-03 | 2023-05-30 | Century Therapeutics, Inc. | Artificial cell death polypeptide for chimeric antigen receptor and uses thereof |
| TW202241935A (zh) | 2020-12-18 | 2022-11-01 | 美商世紀治療股份有限公司 | 具有可調適受體專一性之嵌合抗原受體系統 |
| CN117083375A (zh) * | 2021-01-29 | 2023-11-17 | 艾洛基治疗公司 | 敲低或敲除TAP2、NLRC5、β2m、TRAC、RFX5、RFXAP和RFXANK中的一个或多个以减轻同种异体细胞产物的T细胞识别 |
| MX2023008809A (es) | 2021-01-29 | 2023-08-04 | Allogene Therapeutics Inc | ATENUACIÓN O INACTIVACIÓN DE UNO O MÁS DE TAP2, NLRC5, ß2M, TRAC, RFX5, RFXAP Y RFXANK PARA MITIGAR EL RECONOCIMIENTO DE CÉLULAS T DE PRODUCTOS CELULARES ALOGÉNICOS. |
| CA3209946A1 (en) * | 2021-03-05 | 2022-09-09 | Matthew Angel | Engineered immune cell therapies |
| CN113528453B (zh) * | 2021-07-07 | 2023-05-12 | 金宇保灵生物药品有限公司 | 一种永生化猪巨噬细胞株及其构建方法和应用 |
| GB202110363D0 (en) * | 2021-07-19 | 2021-09-01 | Celyad S A | NKG2D CAR cells expressing IL-18 for adoptive cell therapy |
| EP4504221A4 (en) * | 2022-03-22 | 2026-02-25 | Celyntra Therapeutics Sa | Compositions and methods for generating cells with reduced immunogenicity |
| WO2023233342A2 (en) * | 2022-06-01 | 2023-12-07 | Crispr Therapeutics Ag | Gene-edited natural killer cells |
| WO2024047561A1 (en) * | 2022-09-02 | 2024-03-07 | Janssen Biotech, Inc. | Biomaterials and processes for immune synapse modulation of hypoimmunogenicity |
| WO2024218715A1 (en) | 2023-04-19 | 2024-10-24 | Btl Healthcare Technologies A.S. | Culture media based on protein hydrolysate and a process for preparing thereof |
| WO2025076485A1 (en) * | 2023-10-05 | 2025-04-10 | Mink Therapeutics, Inc. | Novel invariant natural killer t cells and t cell engager compositions and methods of use thereof |
| US12668774B2 (en) | 2023-10-12 | 2026-06-30 | Btl Healthcare Technologies A.S. | Product, system and method of cell cultivation |
| WO2026019829A1 (en) * | 2024-07-15 | 2026-01-22 | A2 Biotherapeutics, Inc. | Compositions and methods for stimulating t cells used in cell therapy with a bispecific bridging molecule |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3789487A1 (en) * | 2013-04-03 | 2021-03-10 | Memorial Sloan Kettering Cancer Center | Effective generation of tumor-targeted t-cells derived from pluripotent stem cells |
| KR20160145186A (ko) | 2014-04-24 | 2016-12-19 | 보드 오브 리전츠, 더 유니버시티 오브 텍사스 시스템 | 입양 세포 요법 생성물을 생성하기 위한 유도 만능 줄기 세포의 응용 |
| EP3166647A4 (en) * | 2014-07-09 | 2018-02-14 | The Regents of the University of California | Engineered invariant natural killer t (inkt) cells and methods of making and using thereof |
| GB201506642D0 (en) * | 2015-04-20 | 2015-06-03 | Ucl Business Plc | T cell receptor |
| ES2803728T3 (es) * | 2015-10-05 | 2021-01-29 | Prec Biosciences Inc | Células genéticamente modificadas que comprenden un gen de región constante alfa del receptor de linfocitos T humano modificado |
| US12642852B1 (en) | 2015-11-04 | 2026-06-02 | Fate Therapeutics, Inc. | Genomic engineering of pluripotent cells |
| KR102614675B1 (ko) | 2016-04-15 | 2023-12-19 | 메모리얼 슬로안 케터링 캔서 센터 | 유전자이식 t 세포 및 키메라 항원 수용체 t 세포 조성물 및 관련 방법 |
| US20200087681A1 (en) * | 2016-12-21 | 2020-03-19 | Ucl Business Plc | Therapeutic cells |
| CN111556892A (zh) * | 2017-12-08 | 2020-08-18 | 菲特治疗公司 | 使用增强的iPSC衍生的效应细胞的免疫疗法 |
| CA3093449A1 (en) * | 2018-03-09 | 2019-09-12 | TCR2 Therapeutics Inc. | Compositions and methods for tcr reprogramming using fusion proteins |
-
2020
- 2020-04-08 CN CN202080031737.3A patent/CN113906133A/zh active Pending
- 2020-04-08 WO PCT/US2020/027327 patent/WO2020210398A1/en not_active Ceased
- 2020-04-08 SG SG11202110601UA patent/SG11202110601UA/en unknown
- 2020-04-08 JP JP2021560206A patent/JP7783746B2/ja active Active
- 2020-04-08 EP EP20787029.6A patent/EP3953453A4/en active Pending
- 2020-04-08 BR BR112021019772A patent/BR112021019772A2/pt unknown
- 2020-04-08 KR KR1020217036036A patent/KR20210139472A/ko not_active Ceased
- 2020-04-08 AU AU2020271523A patent/AU2020271523B2/en active Active
- 2020-04-08 US US17/438,317 patent/US20220184142A1/en active Pending
- 2020-04-08 MX MX2021012054A patent/MX2021012054A/es unknown
- 2020-04-08 CA CA3135224A patent/CA3135224A1/en active Pending
-
2021
- 2021-09-30 IL IL286858A patent/IL286858A/en unknown